Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
- Disease/Condition
- Urothelial Carcinoma
- Drug/Device/Intervention
- Cxbladder urine test
- Study type
- Observational
- Intervention type
- diagnostic test
- Primary sponsor
- Pacific Edge Limited
- Location
- Durham, United States of America
- Phase
- N/A
- Start date
- Sep 01, 2023
- End date
- Apr 01, 2024
- Enrollment
- 1000 participants
The alignment of Cxbladder Detect-plus results with the standard of care diagnostic result for the presence or absence of UC, to validate Cxbladder Detect-plus performance in subjects with microscopic hematuria.
It is of current debate whether the use of invasive (referring to a process that requires
 insertion into the body) standard of care procedures such as a cystoscopy which is a
 procedure to look inside the bladder using a thin camera called a cystoscope, is appropriate
 for use in patients with microscopic hematuria or blood in urine invisible to the naked eye.
 This is because the risk of disease (bladder cancer - urothelial carcinoma) is relatively low
 in this population group, approximately 3%. Invasive procedures such as a cystoscopy comes
 with anxiety and pain, in addition to other potential side effects. This has resulted in low
 admittance in urology clinics for cystoscopy with hematuria (blood in urine) patients.
 Therefore, there is a need for a more simple, non-invasive test that can accurately detect
 the presence or absence of disease (urothelial carcinoma) in patients with microscopic
 hematuria. There is a potential role Cxbladder, a non-invasive, urine based test, can fill
 this role.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05889195
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05889195 through Pure Global AI's free database. This phase not specified trial is sponsored by Pacific Edge Limited and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 1000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.